Ulcer osteoma and periosteal reactions to chronic leg ulcers.

1997 ◽  
Vol 168 (1) ◽  
pp. 155-157 ◽  
Author(s):  
D Karasick ◽  
M E Schweitzer ◽  
D M Deely
Phlebologie ◽  
2009 ◽  
Vol 38 (05) ◽  
pp. 211-218 ◽  
Author(s):  
C. Wax ◽  
A. Körber ◽  
J. Dissemond ◽  
J. Klode

SummaryChronic leg ulcer may have various causes, which are currently not centrally recorded in Germany. It is also unclear who treats patients with chronic leg ulcers in Germany and how the basic implementation of diagnosis and treatment of these patients looks like. Patients, methods: Therefore, we started a survey of 1000 general practitioners and practising specialists in dermatology, surgery and phlebology in five different regions of Germany. We carried out the genesis of a total of 6275 patients from 62 different practising therapists, 33 specialists in dermatology, surgery or phlebology and 29 general practitioners. Results: In 66.1% of all patients we found a venous leg ulcer, in 9.1% a leg ulcer from peripheral arterial occlusive disease, and in 8.5% a mixture of both. Thus there suffered a total of 83.8% of patients on chronic venous insufficiency or peripheral arterial occlusive disease as a major factor in the genesis of the chronic leg ulcer. However, even the rarely diagnosed entities such as exogenous factors, vasculitis, pyoderma gangrenosum or infectious diseases are occur in summation in 16.2% of all patients and should therefore be known and excluded. In addition, the treatment periods and referral routes of patients with chronic leg ulcer should be identified. The analysis showed that the vast majority (86.8%) of patients with chronic ulcers who were investigated by us is treated by specialists. The treatment duration of general practitioners is 6.3 weeks (mean value) before the patient will be referred to a specialist. This treatment period is significantly shorter compared to the treatment period of the specialists, who treat their patients 14.1 weeks (mean value) before the patient will be referred to another specialist or to a clinic. Conclusion: Our results show the current aspects of aetiology and the way of treatment of patients with chronic leg ulcers in Germany.


2008 ◽  
Vol 11 (6) ◽  
pp. A627
Author(s):  
M Augustin ◽  
L Grams ◽  
K Herberger ◽  
N Franzke ◽  
S Debus ◽  
...  

2020 ◽  
Vol 9 (1) ◽  
Author(s):  
Oluwatoyin A. Babalola ◽  
Ayodele Ogunkeyede ◽  
Abayomi B. Odetunde ◽  
Foluke Fasola ◽  
Anthony A. Oni ◽  
...  

2018 ◽  
Vol 72 (12) ◽  
pp. e13263 ◽  
Author(s):  
Ut T. Bui ◽  
Kathleen Finlayson ◽  
Helen Edwards

2016 ◽  
Vol 25 (Sup9) ◽  
pp. S23-S29 ◽  
Author(s):  
A. Massimiliano D'Erme ◽  
M. Iannone ◽  
V. Dini ◽  
M. Romanelli

2021 ◽  
Vol 33 (11) ◽  
pp. 285-295
Author(s):  
Jacek Mikosinski ◽  
Anna Di Landro ◽  
Karolina Kasztalska-Kazmierczak ◽  
Emilie Soriano ◽  
Carol Caverzasio ◽  
...  

Introduction. Topical applications of hyaluronic acid (HA)–containing formulations, based on the complex and vital role of HA in all stages of the wound-healing process, are routinely used with standard therapy to promote faster healing of chronic wounds. However, evidence to guide clinical decisions on the use of topical HA in the healing of vascular leg ulcers is limited. Objective. This study compared the efficacy and safety of topical application of a hyaluronic acid cream vs a neutral comparator (identical cream without HA) in treating subjects with chronic leg ulcers of vascular origin. Materials and Methods. This was a prospective, multicenter double-blind randomized controlled trial. One hundred sixty-eight subjects with chronic leg ulcers of venous or mixed (venous and arterial) origin were randomized to receive either topical applications of 0.2% HA cream or neutral comparator cream for a maximum of 20 weeks. The primary efficacy endpoint was complete ulcer healing (100% reepithelialization of the wound area centrally assessed at 20 weeks or before and confirmed 3 weeks later). In both groups, topical treatment was associated with standard therapy (ulcer cleansing and optimized compression). Results. The proportion of subjects with centrally assessed complete healing of the target ulcer that was confirmed 3 weeks later (primary efficacy endpoint) was substantially higher in the HA cream group (31.3%) than in the neutral cream group (14.8%; P =.009). Results in the full analysis, per protocol, and as assessed by the investigator were consistent with primary results. No significant difference in treatment effect was observed when subjects were stratified according to baseline ulcer size (≤20 cm2 or >20 cm2) regardless of topical treatment. Safety and tolerability were comparable between treatments. Conclusions. Treatment of subjects with chronic leg ulcers of venous or mixed origin with HA cream is safe, well tolerated, and results in a higher rate of healing than a neutral comparator cream.


Sign in / Sign up

Export Citation Format

Share Document